Andere Sprachen Spectral Medical Inc.

Aktien

A12HJ9

CA8475771033

EDT

Verzögert Toronto S.E. Andere Börsenplätze 19:24:15 26.04.2024			% 5 Tage	% 1. Jan.
0.46 ^CAD	+2.22%		+4.55%	+8.24%

10.04.	Spectral Medical gibt Update zur Tigris-Studie	CI
02.04.	Spectral Medical Inc. kündigt Änderungen im Vorstand an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Spectral Medical Updated on Tigris Trial	10.04.
Spectral Medical Brief: Providing Tigris Trial Update; 101 patients enrolled	10.04.
Spectral Medical Provides Tigris Trial Update	10.04.
Spectral Medical Provides Tigris Trial Update	10.04.
North American Morning Briefing : Investors on -2-	05.04.
Spectral Medical Brief: Paul Walker will immediately succeed Bihl as Chair	02.04.
Spectral Medical Brief: Anthony Bihl III, Spectral's Chairman, will be retiring from the Board at Upcoming Shareholder Meeting in June 2024	02.04.
Spectral Medical Chair to Retire From the Board of Directors	02.04.
Spectral Medical Inc. Announces Board Changes	02.04.
Spectral Medical Brief: Says Total of 97 patients randomized to date out of the 150 total patients to be enrolled in the Tigris trial	28.03.
Spectral Medical Brief: Q4 Revenue $365,000; Loss was $6,479,000, or $0.02 per share	28.03.
Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update	28.03.
Spectral Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
North American Morning Briefing : Stocks Struggle After New Records	22.03.
Spectral Medical Provides February Tigris Trial Update	28.02.
Spectral Medical Inc. Provides Update on the Company's Tigris Trial	28.02.
Spectral Medical Brief: Providing February Tigris Trial Update; 93 patients enrolled; February represents a second record breaking consecutive month for patient enrollment	28.02.
Spectral Medical Provides February Tigris Trial Update	28.02.
Spectral Medical Says PMX Distribution and Supply Agreement with Baxter International Extended for 10 Years	21.02.
Spectral Medical Brief: Baxter to act as Exclusive partner to Spectral for 10 years following PMX approval by U.S. FDA	21.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Spectral Medical Inc.

Aktien

A12HJ9

CA8475771033

EDT

Andere Sprachen

Filter